CN103463645A - 一种鱼类溶藻弧菌抗独特型抗体基因工程疫苗及其制备方法 - Google Patents
一种鱼类溶藻弧菌抗独特型抗体基因工程疫苗及其制备方法 Download PDFInfo
- Publication number
- CN103463645A CN103463645A CN201210183806XA CN201210183806A CN103463645A CN 103463645 A CN103463645 A CN 103463645A CN 201210183806X A CN201210183806X A CN 201210183806XA CN 201210183806 A CN201210183806 A CN 201210183806A CN 103463645 A CN103463645 A CN 103463645A
- Authority
- CN
- China
- Prior art keywords
- gene
- idiotype antibody
- antibody
- alginolyticus
- vibrio alginolyticus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003302 anti-idiotype Effects 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 5
- 238000010353 genetic engineering Methods 0.000 title abstract description 10
- 229960005486 vaccine Drugs 0.000 title abstract description 8
- 241000607598 Vibrio Species 0.000 title abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 50
- 241000607594 Vibrio alginolyticus Species 0.000 claims abstract description 39
- 230000014509 gene expression Effects 0.000 claims abstract description 15
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 241000588724 Escherichia coli Species 0.000 claims abstract description 9
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 9
- 235000001014 amino acid Nutrition 0.000 claims abstract description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims abstract description 8
- 230000000295 complement effect Effects 0.000 claims abstract description 6
- 239000000047 product Substances 0.000 claims description 26
- 239000013612 plasmid Substances 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229940124551 recombinant vaccine Drugs 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 230000004087 circulation Effects 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 5
- 238000011156 evaluation Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 108091008146 restriction endonucleases Proteins 0.000 claims description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004153 renaturation Methods 0.000 claims description 3
- 238000002525 ultrasonication Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 15
- 102000036639 antigens Human genes 0.000 abstract description 15
- 108091007433 antigens Proteins 0.000 abstract description 15
- 230000036039 immunity Effects 0.000 abstract description 10
- 230000005847 immunogenicity Effects 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 8
- 241000251468 Actinopterygii Species 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 7
- 238000002965 ELISA Methods 0.000 abstract description 5
- 230000003053 immunization Effects 0.000 abstract description 4
- 238000002649 immunization Methods 0.000 abstract description 4
- 230000009465 prokaryotic expression Effects 0.000 abstract description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract description 2
- 239000013604 expression vector Substances 0.000 abstract description 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 235000019688 fish Nutrition 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 241000252087 Anguilla japonica Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000269979 Paralichthys olivaceus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- GTDOPRQDTRLYAL-UHFFFAOYSA-N hydrogen peroxide;methanol Chemical compound OC.OO GTDOPRQDTRLYAL-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210183806XA CN103463645A (zh) | 2012-06-06 | 2012-06-06 | 一种鱼类溶藻弧菌抗独特型抗体基因工程疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210183806XA CN103463645A (zh) | 2012-06-06 | 2012-06-06 | 一种鱼类溶藻弧菌抗独特型抗体基因工程疫苗及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103463645A true CN103463645A (zh) | 2013-12-25 |
Family
ID=49788831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210183806XA Pending CN103463645A (zh) | 2012-06-06 | 2012-06-06 | 一种鱼类溶藻弧菌抗独特型抗体基因工程疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103463645A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104531568A (zh) * | 2014-12-12 | 2015-04-22 | 福建省水产研究所 | 抗河豚毒素单链抗体及其制备方法 |
CN108601833A (zh) * | 2016-02-01 | 2018-09-28 | 伊莱利利公司 | 甲状旁腺激素-抗rankl抗体融合化合物 |
CN114099657A (zh) * | 2021-11-04 | 2022-03-01 | 暨南大学 | 一种溶藻弧菌减毒活疫苗及其制备方法与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101955940A (zh) * | 2010-09-03 | 2011-01-26 | 付建芳 | 抗溶藻弧菌独特型单克隆抗体可变区的基因序列 |
-
2012
- 2012-06-06 CN CN201210183806XA patent/CN103463645A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101955940A (zh) * | 2010-09-03 | 2011-01-26 | 付建芳 | 抗溶藻弧菌独特型单克隆抗体可变区的基因序列 |
Non-Patent Citations (2)
Title |
---|
付建芳 等: "抗溶藻弧菌独特型单克隆抗体单链抗体ScFv 的构建和表达", 《中国免疫学杂志》 * |
付建芳: "溶藻弧菌抗独特型抗体基因工程疫苗的研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104531568A (zh) * | 2014-12-12 | 2015-04-22 | 福建省水产研究所 | 抗河豚毒素单链抗体及其制备方法 |
CN108601833A (zh) * | 2016-02-01 | 2018-09-28 | 伊莱利利公司 | 甲状旁腺激素-抗rankl抗体融合化合物 |
CN114099657A (zh) * | 2021-11-04 | 2022-03-01 | 暨南大学 | 一种溶藻弧菌减毒活疫苗及其制备方法与应用 |
CN114099657B (zh) * | 2021-11-04 | 2022-05-17 | 暨南大学 | 一种溶藻弧菌减毒活疫苗及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101891806A (zh) | 抗黄病毒包膜e蛋白的单克隆抗体及其应用 | |
CN107226861A (zh) | 人源抗h7n9禽流感病毒中和性抗体1f7l及其应用 | |
CN104017080B (zh) | 一种犬源单链抗体及其构建方法和应用 | |
CN101451145B (zh) | 基于t细胞表位的结核基因疫苗及其制备方法和应用 | |
CN109536507A (zh) | 布氏鲳鲹抗菌肽基因及其编码的肽和原核表达制备方法 | |
CN107630024A (zh) | 编码h5亚型禽流感病毒血凝素蛋白的基因及其应用 | |
CN107840889A (zh) | 高亲和力的抗cd123抗体及其应用 | |
CN103463645A (zh) | 一种鱼类溶藻弧菌抗独特型抗体基因工程疫苗及其制备方法 | |
CN102558306A (zh) | 用于防治旋毛虫病的抗原表位、其组合物及用途 | |
WO2020119664A1 (zh) | 抗h7n9全人源单克隆抗体2g3及其制法与应用 | |
CN103725697A (zh) | 化学合成的金黄色葡萄球菌的表面蛋白FnBPA基因片段及其表达、应用 | |
CN101337990B (zh) | 人源抗狂犬病毒中和性抗体及其制备方法与用途 | |
CN101602809B (zh) | 具有抗炎作用的抗体靶向补体抑制物 | |
CN101235086B (zh) | 重组人抗狂犬病毒抗体 | |
CN107827981B (zh) | 抗绿脓杆菌外毒素a的纳米抗体及其应用 | |
CN105504053A (zh) | 一种猪流行性腹泻病毒m蛋白特异性重链抗体 | |
CN103130894B (zh) | 抗人γδTCR单克隆抗体的重组单链抗体G5‑4ScFv及其编码基因与应用 | |
CN106754740A (zh) | 小鼠抗人mdr‑1单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN108148137A (zh) | 一种高亲和力的b7h4/1e10单克隆抗体及其应用 | |
CN104945513B (zh) | 变形链球菌细胞表面蛋白抗原(SpaP)和葡糖基转移酶(GtfB)融合蛋白疫苗及其制备方法 | |
CN101429247A (zh) | 抗日本血吸虫病天然分子疫苗特异性单链抗体 | |
CN112843225A (zh) | 一种基于RA OmpA基因鸭疫里默氏杆菌DNA疫苗及其制备方法和鉴定方法 | |
CN101357942B (zh) | 一种中和肠出血性大肠杆菌0157:H7志贺毒素Ⅱ的单克隆抗体、Fab抗体与应用 | |
CN105085638A (zh) | KSHV病毒vIRF4 DNA结合域、其多克隆抗体及制备方法 | |
CN101357944B (zh) | 血吸虫抗独特型抗体NP30嵌合Fab抗体片段及制备方法、应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: THE 4TH MILITARY SURGEON UNIV. P. L. A. Free format text: FORMER OWNER: FU JIANFANG Effective date: 20150519 Free format text: FORMER OWNER: TU YANYANG FU JUFANG HUANG WEIQUAN Effective date: 20150519 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150519 Address after: 710032 Changle West Road, Shaanxi, China, No. 127, No. Applicant after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: 710032 Changle West Road, Shaanxi, China, No. 127, No. Applicant before: Fu Jianfang Applicant before: Tu Yanyang Applicant before: Fu Jufang Applicant before: Huang Weiquan |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131225 |